Authors
Latest:
Updates in the Use of Liquid Biopsies for Multiple Tumor TypesWafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses updates in the use of liquid biopsies for multiple tumor types during the 2018 ASCO Annual Meeting.
Latest:
Third-Line Eribulin Effective, Safe in Metastatic Breast CancerAmong patients with HER2-negative stage IIIb/IV breast cancer who have progressed after a taxane or anthracycline therapy, a multicenter single-arm study of third-line eribulin demonstrated both safety and efficacy.
Latest:
Radiation Therapy Dose for the Treatment of Patients With Lung CancerWalter J. Curran, Jr., MD, FACR, associate vice president of cancer, Woodruff Health Sciences Center, executive director, Winship Cancer Institute, Lawrence W. Davis Chair of Radiation Oncology, Emory University, discusses radiation therapy dose for the treatment of patients with lung cancer.
Latest:
Dr. Walter Weder on Mesothelioma ChallengesWalter Weder, MD, University Hospital, Division of Thoracic Surgery, discusses challenges in mesothelioma treatment and why specialized centers are best for the patient.
Latest:
New Options for Overcoming Resistance to Anti-VEGF Therapy in HCCWasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shares his expert opinion on the importance of the phase III IMbrave150 trial, which evaluated a targeted therapy combination in patients with hepatocellular carcinoma.<br />
Latest:
BGB-11417 +/- Zanubrutinib Demonstrates Early Efficacy Signals in CLL/SLLPhase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia.
Latest:
PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate CancerWith the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.
Latest:
Considering Radiation and Preoperative Therapy Options in Locally Advanced GEJ CancersWeijing Sun, MD, discusses a major topic in locally advanced gastroesophageal junction adenocarcinoma covered at the 2018 ISGIO Annual Conference in Arlington, Virginia.
Latest:
Current Management of Pancreatic CancerRecent therapeutic advances have almost doubled the survival of patients with metastatic pancreatic cancer, and the availability of highly active chemotherapy regimens is making personalized medicine a reality.
Latest:
FDA Issues Draft Guidance to Broaden Clinical Trial InclusionThe FDA recently released 5 new draft guidance documents that promote broader patient eligibility for cancer clinical trials. The policies encourage inclusion of certain individuals who were previously disqualified due to medical conditions or biological factors, including brain metastases, organ dysfunction, prior or concurrent malignancies, chronic infections, and age.
Latest:
Detecting the MET Exon 14 Skipping Mutations in NSCLCWillemina R. Geurts-Giele, PhD, discusses 2 approaches used to detect the MET exon 14 skipping mutation in patients with non-small cell lung cancer.
Latest:
Olaratumab Plus Doxorubicin in Advanced Soft Tissue SarcomaWilliam D. Tap, MD, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
Latest:
Exploring Why Venetoclax and Ibrutinib Have Synergy in the CLL PopulationWilliam G. Wierda, MD, PhD, discusses the synergy between ibrutinib and venetoclax in patients with chronic lymphocytic leukemia.
Latest:
Choosing Therapies for Early-Stage HER2+ Breast CancerWilliam J. Gradishar, MD, discusses the choice of adjuvant or neoadjuvant regimens for patients with HER2-positive breast cancer.
Latest:
Addressing Challenges With New Therapies in Prostate CancerWilliam K. Oh, MD, discusses phase III studies in the prostate cancer setting which led to the use of these new treatments, such as androgen receptor targeted therapies with chemotherapy in earlier disease settings.
Latest:
Evaluating Significance of ENZAMET Trial in Metastatic Hormone-Sensitive Prostate CancerWilliam K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.
Latest:
Selecting Therapy for Patients with CRPCWilliam Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.
Latest:
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot StudyAlthough there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Latest:
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to TreatmentWilliam Sikov, MD, associate director of Clinical Research, Program in Women
Latest:
Dr. William Wierda on Ibrutinib and Idelalisib as Treatments in NSCLCWilliam G. Wierda, MD, PhD, discusses ibrutinib and idelalisib as treatments for non-small cell lung cancer. Wierda says that as it currenlty stands, ibrutinib is approved only for patients with NSCLC with a 17p deletion untreated and idelalisib is only approved for patients with untreated NSCLC.
Latest:
Treatments Improve PFS in Thyroid CancerWinston Tan, MD, discusses 2 agents that have advanced the treatment landscape for patients with thyroid cancer, including the multi-tyrosine kinase inhibitor lenvatinib and another TKI, sorafenib.
Latest:
Exploring Immunotherapy in Brain CancerW. K. Alfred Yung, MD, a professor of Neuro-oncology at MD Anderson Cancer Center, discusses the future of immuno-oncology in the treatment landscape of brain cancer.
Latest:
Use of Somatostatin Analogs in Patients With Neuroendocrine TumorsWouter W. de Herder, MD, PhD, professor of Endocrine Oncology, Erasmus MC, discusses the use of somatostatin analogs in patients with neuroendocrine tumors, as well as significant clinical trials investigating these agents.
Latest:
Current Role of MET Inhibitors in Cancer TherapyEmerging discoveries of MET chromosomal fusions provide additional promise as therapeutic genomic targets in MET cancer therapy and would need to be tested vigorously.
